Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues

Indian Journal of Urology

Volumn 25, Issue 2, 2009, Pages 169-176

  Bagrodia, Aditya ^a   DiBlasio, Christopher ^a   Wake, Robert ^a   Derweesh, Ithaar ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Androgen deprivation therapy; Complications; Prostate cancer

Indexed keywords

BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CLONIDINE; ESTROGEN; GONADORELIN AGONIST; LEUPRORELIN; MEGESTROL ACETATE; PAMIDRONIC ACID; PAROXETINE; PHOSPHODIESTERASE V INHIBITOR; POLYESTRADIOL PHOSPHATE; PROGESTERONE; VENLAFAXINE; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DIET THERAPY; ENDOCRINE DISEASE; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FRACTURE; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MALE SEXUAL DYSFUNCTION; METABOLIC SYNDROME X; MORBIDITY; ORCHIECTOMY; OSTEOPOROSIS; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SUDDEN DEATH; TREATMENT DURATION; VACUUM ASSISTED CLOSURE; VASOMOTOR DISORDER;

EID: 67651238522     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.52907     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002;52:154-179 (Pubitemid 34546107)
3. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300. (Pubitemid 27318990)
4. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003;95:981-991
5. Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002;94:430-437 (Pubitemid 34285092)
6. Dacal K, Sereika SM, Greenspan SL. Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc 2006;54:85-90.
7. Diblasio CJ, Hammett J, Malcolm JB, Womack JH, Kincade MC, Mancini J, et al. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. BJU Int 2008;102:39-43. (Pubitemid 351799441)
8. Green HJ, Pakenham KI, Headley BC, Gardiner RA. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring. Psychooncology 2002;11:401-414
9. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: A randomized controlled trial. BJU Int 2004;93:975-979 (Pubitemid 38758617)
10. Fowler FJ Jr, McNaughton Collins M, Walker Corkery E, Elliott DB, Barry MJ. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 2002;95:287-295 (Pubitemid 34787594)
11. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, et al. EAU guidelines on prostate cancer. Eur Urol 2005;48:546-551
12. DiBlasio CJ, Malcolm JB, Derweesh IH, Womack JH, Kincade MC, Mancini JG, et al. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer BJU Int 2008;102:39-43.
13. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, et al. Quality-of-life outcomes after primary androgen deprivation therapy: Results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001;19:3750-3757 (Pubitemid 32844788)
14. Naoe M, Ogawa Y, Shichijo T, Fuji K, Fukagai T, Yoshida H. Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flash patients under androgen-deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis 2006;9:275-278 (Pubitemid 44334701)
15. Spetz AC, Hammar M, Lindberg B, Spangberg A, Varenhorst E; Scandinavian Prostatic Cancer Group-5 Trial Study. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol 2001;166:517-520
16. Holzbeierlein JM. Managing complications of androgen deprivation therapy for prostate cancer. Urol Clin North Am 2006;33:181-90, vi.
17. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006;106:581-588 (Pubitemid 43157621)
18. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006;24:3979-3983 (Pubitemid 46630747)
19. Derweesh IH, Diblasio CJ, Kincade MC, Malcolm JB, Lamar KD, Patterson AL, et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 2007;100:1060-1065
20. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-4456 (Pubitemid 46630983)
21. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:599-603. (Pubitemid 34158224)
22. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006;91:1305-1308
23. Haffner SM, Mykkanen L, Valdez RA, Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993;77:1610-1615 (Pubitemid 24000922)
24. Khaw KT, Barrett-Connor E. Blood pressure and endogenous testosterone in men: An inverse relationship. J Hypertens 1988;6:329-332 (Pubitemid 18123015)
25. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003;104:195-201. (Pubitemid 36238052)
26. Malcolm JB, Diblasio CJ, Womack JH, Kincade MC, Ogles M, Mancini J, et al. Association of cerebrovascular accident and myocardial infarction with Androgen Deprivation Therapy. J Urol 2007;177:200.
27. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99:1516-1524 (Pubitemid 351767235)
28. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997;12:1761-1768
29. Smith MR. Androgen deprivation therapy for prostate cancer: New concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007;14:247-254 (Pubitemid 46684481)
30. Malcolm JB, Derweesh IH, Kincade MC, DiBlasio CJ, Lamar KD, Wake RW, et al. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urol 2007;14:3551-3559
31. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-164 (Pubitemid 40096612)
32. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006;175:136-9; discussion 139. (Pubitemid 41797111)
33. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:7897-7903 (Pubitemid 46657388)
34. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161:1219-1222 (Pubitemid 29426121)
35. Leder BZ, Smith MR, Fallon MA, Lee ML, Finkelstein JS. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab 2001;86:511-516
36. Goldray D, Weisman Y, Jaccard N, Merdler C, Chen J, Matzkin H. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab 1993;76:288-290 (Pubitemid 23073043)
37. Higano CS. Management of bone loss in men with prostate cancer. J Urol 2003;170:S59-63; discussion S64.
38. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies. Cancer 2004;100:892-899 (Pubitemid 38222847)
39. Diamond TH, Winters J, Smith A, De Souza P, Kersley JH, Lynch WJ, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: A double blind, randomized, placebo-controlled crossover study. Cancer 2001;92:1444-1450 (Pubitemid 32947828)
40. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-2012 (Pubitemid 36576705)
41. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-955 (Pubitemid 34940810)